Ramtin Agah bought $169 of RNXT
Chief Medical Officer at RenovoRx, Inc.. 205 shares at an average of $0.83, traded Dec 30, 2025, filed Jan 2, 2026.
Score components
- +15RoleOfficer
- 0Trade size$169 at market
- -5Relative to holdingsUnder 1% of holdings (0.0%)
- +8Price context43% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- +5Repeat buying4 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +24.6%, 3m +17.4%, 6m +10.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-26-000157, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 30, 2025 | POpen-market purchase Common Stock | +205 | $0.83 | $169 | 778,665 | Jan 2, 2026 |
Related signals
Other insiders at RenovoRx, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 46Moderate | RNXTbuy RenovoRx, Inc. | Mark Voll Chief Financial Officer | $20k 25,000 shares | +21% | |
| 28Weak | RNXTbuy RenovoRx, Inc. | Ramtin Agah Chief Medical Officer | $9,975 10,000 shares | +1% | |
| 36Weak | RenovoRx, Inc. | Ramtin Agah Chief Medical Officer | $8,424 9,795 shares | +1% | |
| 46Moderate | RenovoRx, Inc. | Shaun Bagai Chief Executive Officer | $4,507 5,000 shares | +1% | |
| 41Moderate | RenovoRx, Inc. | Shaun Bagai Chief Executive Officer | $4,262 5,000 shares | +2% | |
| 36Weak | RenovoRx, Inc. | Ramtin Agah Chief Medical Officer | $10k 12,000 shares | +2% | |
| 36Weak | RenovoRx, Inc. | Ramtin Agah Chief Medical Officer | $9,600 10,000 shares | +1% | |
| 33Weak | RNXTbuy RenovoRx, Inc. | Ramtin Agah Chief Medical Officer | $18k 22,000 shares | +3% | |
| 33Weak | RNXTbuy RenovoRx, Inc. | Shaun Bagai Chief Executive Officer | $9,297 10,000 shares | +3% | |
| 25Weak | RNXTbuy RenovoRx, Inc. | Ramtin Agah Chief Medical Officer | $29k 21,000 shares | +3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.